EP1565456B1 — 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
Assigned to CJ CheilJedang Corp · Expires 2008-10-01 · 18y expired
What this patent protects
A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided: wherein: R<SUB>1 </SUB>represents naphthyl, indolyl, benzof…
USPTO Abstract
A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided: wherein: R<SUB>1 </SUB>represents naphthyl, indolyl, benzofuranyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzotriazolyl, benzooxazolyl, quinolinyl, or isoquinolinyl; wherein, R<SUB>1 </SUB>is optionally substituted at a substitutable position with one or more radicals independently selected from halogen, hydroxy, nitro, C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl, C<SUB>1</SUB>-C<SUB>6 </SUB>haloalkyl, C<SUB>1</SUB>-C<SUB>6 </SUB>alkoxy, C<SUB>1</SUB>-C<SUB>6 </SUB>haloalkoxy, cyano, amino, monoalkylamino, and dialkylamino; R<SUB>2 </SUB>represents methyl or amino; and A, B, E, and D each independently represent carbon or nitrogen.
Drugs covered by this patent
- Xalkori (crizotinib) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.